Shares of U.S. Bioscience Inc. rose $7.50 to $47.13 on Tuesdayafter the company announced that a Food and DrugAdministration advisory panel will review Ethyol by Jan. 31.
Ethyol protects normal tissue, including stem cells, from theeffects of chemotherapy. Dr. Philip Schein, chairman and chiefexecutive, said the drug's toxicity profile compares favorablywith that of colony stimulating factors. CSFs, which stimulatestem cells to produce white blood cells, and Ethyol could becomplementary treatments. Ethyol is also being developed as aradiation-protective agent.
In a presentation to the Robertson, Stephens & Co. EighthAnnual Medical Conference, Schein also said the companyhopes to submit a new drug application in January forTrimetrexate to treat Pneumocystis carinii pneumonia andtoxoplasmosis in AIDS patients.
The West Conshohocken, Pa., company (AMEX:UBS) alsoannounced an agreement in principle granting Schering-PloughCorp. marketing rights for certain countries in Latin Americaand the Far East to Ethyol, Hexalen, WR-151327, PALA andRogletimide.
Hexalen in December received FDA approval for treatment ofrefractory ovarian cancer. PALA is being developed to enhancethe activity of certain chemotherapeutic agents. Rogletimide isin development to treat breast cancer. WR-151327 is an oralform of Ethyol.
U.S. Bioscience also said that it has reached an agreement inprinciple to acquire from Rhone-Poulenc Rorer marketingrights to Hexalen in certain European countries.
(c) 1997 American Health Consultants. All rights reserved.